Mhyosphere PCV ID Euroopa Liit - eesti - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - sead - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Suiseng Diff/A Euroopa Liit - eesti - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - sead - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Isoflutek inhalatsiooniaur, vedelik Eesti - eesti - Ravimiamet

isoflutek inhalatsiooniaur, vedelik

laboratorios karizoo s.a. - isofluraan - inhalatsiooniaur, vedelik - 1000mg 1g 250ml 1tk

METOCLOPRAMIDE BASI süste-/infusioonilahus Eesti - eesti - Ravimiamet

metoclopramide basi süste-/infusioonilahus

laboratorios basi industria farmaceutica s.a. - metoklopramiid - süste-/infusioonilahus - 5mg 1ml 2ml 50tk

PARACETAMOL BASI infusioonilahus Eesti - eesti - Ravimiamet

paracetamol basi infusioonilahus

laboratorios basi industria farmaceutica s.a. - paratsetamool - infusioonilahus - 10mg 1ml 100ml 50tk

ATRAKUURIUMBESILAAT BASI süste-/infusioonilahus Eesti - eesti - Ravimiamet

atrakuuriumbesilaat basi süste-/infusioonilahus

laboratorios basi industria farmaceutica s.a. - atrakuuriumbesilaat - süste-/infusioonilahus - 10mg 1ml 5ml 5tk; 10mg 1ml 2.5ml 10tk; 10mg 1ml 5ml 10tk; 10mg 1ml 2.5ml 5tk

FENTANYL BASI süste-/infusioonilahus Eesti - eesti - Ravimiamet

fentanyl basi süste-/infusioonilahus

laboratorios basi industria farmaceutica s.a. - fentanüül - süste-/infusioonilahus - 50mcg 1ml 10ml 50tk; 50mcg 1ml 10ml 10tk; 50mcg 1ml 5ml 50tk; 50mcg 1ml 5ml 10tk

TRAMADOL BASI süstelahus Eesti - eesti - Ravimiamet

tramadol basi süstelahus

laboratorios basi industria farmaceutica s.a. - tramadool - süstelahus - 50mg 1ml 2ml 50tk

IBANDRONIC ACID LICONSA 150 MG õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

ibandronic acid liconsa 150 mg õhukese polümeerikattega tablett

laboratorios liconsa s.a. - ibandroonhape - õhukese polümeerikattega tablett - 150mg 3tk; 150mg 1tk

TARNASOL õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

tarnasol õhukese polümeerikattega tablett

laboratorios liconsa s.a. - losartaan - õhukese polümeerikattega tablett - 50mg 10tk; 50mg 7tk; 50mg 21tk; 50mg 105tk; 50mg 210tk